Visceral leishmaniasis in a woman treated with risankizumab for guttate psoriasis

Key Points

• Visceral leishmaniasis developed in a patient after risankizumab therapy.
• The timing of infection relates closely to the initiation of treatment.
• Risankizumab, targeting specific immune responses, correlates with increased infection risk.
• Proper screening and monitoring for infections are crucial in immunosuppressed patients.